Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Blood biomarkers predict conversion from cognitively stable to mild cognitive impairment or Alzheimer's disease in Down syndrome at 16-month follow-up in ABC-DS.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Age predicts Alzheimer's in Down syndrome better than MRI, plasma, or cognition.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Comprehensive Demographic Correction Improves Sensitivity and Reduces Bias in Cognitive Assessment.

medRxiv : the preprint server for health sciences·2026
Same author

Greater choroid plexus volume is linked to poor sleep, neurodegeneration, and cognitive deficits in older adults: Evidence from the IGNITE Study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Inflammatory, metabolic, and vascular pathways linking cardiorespiratory fitness to cognition: Results from the IGNITE study.

Brain, behavior, & immunity - health·2026
Same author

Patient cerebral organoids capture Alzheimer's disease proteomic biomarkers and drug targets.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: May 27, 2026

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
08:29

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans

Published on: December 18, 2016

Neuropsychiatric profiles in dementia.

David K Johnson1, Amber S Watts, Benjamin A Chapin

  • 1Gerontology Center, University of Kansas, Lawrence, USA. dkj@ku.edu

Alzheimer Disease and Associated Disorders
|November 17, 2011
PubMed
Summary

Neuropsychiatric symptoms vary significantly across dementia types, including Alzheimer disease and vascular dementia. Understanding these distinct symptom profiles aids in managing noncognitive aspects of dementia.

More Related Videos

Development of a Virtual Reality Assessment of Everyday Living Skills
10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

Related Experiment Videos

Last Updated: May 27, 2026

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
08:29

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans

Published on: December 18, 2016

Development of a Virtual Reality Assessment of Everyday Living Skills
10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

Area of Science:

  • Neurology
  • Psychiatry
  • Gerontology

Background:

  • Neuropsychiatric symptoms are common in dementia but vary by type.
  • Identifying these patterns is crucial for effective patient management.
  • Previous research has not comprehensively compared symptom profiles across multiple dementia subtypes.

Purpose of the Study:

  • To compare neuropsychiatric symptom patterns across Alzheimer disease (AD), vascular dementia (VAD), dementia with Lewy bodies (DLB), and Parkinson disease dementia (PDD).
  • To examine symptom profiles in mixed dementia groups (AD/VAD, AD/DLB).
  • To identify a common psychiatric symptom model across dementia types.

Main Methods:

  • Confirmatory factor analysis of Neuropsychiatric Inventory Questionnaire data.
  • Analysis of 2,963 individuals from the National Alzheimer's Coordinating Center Uniform Data Set.
  • Comparison of symptom severity ratings for individuals with Clinical Dementia Rating scores ≥1.

Main Results:

  • A shared 3-factor model (mood, psychotic, frontal symptoms) was identified across all dementia types.
  • Vascular dementia showed the highest symptom levels; Parkinson disease dementia showed the lowest.
  • Alzheimer disease exhibited moderate symptom levels; DLB and mixed dementias had complex profiles.
  • Depressed mood was the most prevalent symptom in mild dementia diagnoses.

Conclusions:

  • Distinct neuropsychiatric symptom profiles characterize different dementia types.
  • These profiles offer valuable insights into the noncognitive symptoms of dementia.
  • Understanding these differences can inform targeted interventions and care strategies.